Background & aims: It has been proposed that serum hepatitis B core-related antigen (HBcrAg) reflects intrahepatic covalently closed circular (ccc)DNA levels. However, the correlation of HBcrAg with serum and intrahepatic viral markers and liver histology has not been comprehensively investigated in a large sample. We aimed to determine if HBcrAg could be a useful therapeutic marker in patients with chronic hepatitis B.
Methods: HBcrAg was measured by chemiluminescent enzyme immunoassay in 130 (36 hepatitis B e antigen [HBeAg]+ and 94 HBeAg-) biopsy proven, untreated, patients with chronic hepatitis B. HBcrAg levels were correlated with: a) serum hepatitis B virus (HBV)-DNA, quantitative hepatitis B surface antigen and alanine aminotransferase levels; b) intrahepatic total (t)HBV-DNA, cccDNA, pregenomic (pg)RNA and cccDNA transcriptional activity (defined as pgRNA/cccDNA ratio); c) fibrosis and necroinflammatory activity scores.
Results: HBcrAg levels were significantly higher in HBeAg+ vs. HBeAg- patients and correlated with serum HBV-DNA, intrahepatic tHBV-DNA, pgRNA and cccDNA levels, and transcriptional activity. Patients who were negative for HBcrAg (<3 LogU/ml) had less liver cccDNA and lower cccDNA activity than the HBcrAg+ group. Principal component analysis coupled with unsupervised clustering identified that in a subgroup of HBeAg- patients, higher HBcrAg levels were associated with higher serum HBV-DNA, intrahepatic tHBV-DNA, pgRNA, cccDNA transcriptional activity and with higher fibrosis and necroinflammatory activity scores.
Conclusions: Our results indicate that HBcrAg is a surrogate marker of both intrahepatic cccDNA and its transcriptional activity. HBcrAg could be useful in the evaluation of new antiviral therapies aiming at a functional cure of HBV infection either by directly or indirectly targeting the intrahepatic cccDNA pool.
Lay summary: Hepatitis B virus causes a chronic infection which develops into severe liver disease and liver cancer. The viral covalently closed circular DNA (cccDNA) is responsible for the persistence of the infection in hepatocytes. To better manage patient treatment and follow-up, and to develop new antiviral treatments directly targeting the intrahepatic pool of cccDNA, serum surrogate markers reflecting the viral activity in the liver are urgently needed. In this work, we demonstrate that quantification of hepatitis B core-related antigen in serum correlates with cccDNA amount and activity and could be used to monitor disease progression.
Keywords: Biomarker; Chronic hepatitis B (CHB); Covalently closed circular DNA (cccDNA); Hepatitis B virus (HBV); Patient management; Pregenomic RNA (pgRNA).
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.J Clin Microbiol. 2019 Jan 2;57(1):e01303-18. doi: 10.1128/JCM.01303-18. Print 2019 Jan. J Clin Microbiol. 2019. PMID: 30355757 Free PMC article.
Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.Liver Int. 2017 Jul;37(7):995-1001. doi: 10.1111/liv.13346. Epub 2017 Jan 28. Liver Int. 2017. PMID: 27992681
Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.J Gastroenterol Hepatol. 2013 Jul;28(7):1217-22. doi: 10.1111/jgh.12182. J Gastroenterol Hepatol. 2013. PMID: 23432697
Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Aliment Pharmacol Ther. 2018 Jan;47(1):43-54. doi: 10.1111/apt.14376. Epub 2017 Oct 16. Aliment Pharmacol Ther. 2018. PMID: 29035003 Review.
The Role of Hepatitis B Core-Related Antigen.Genes (Basel). 2019 May 9;10(5):357. doi: 10.3390/genes10050357. Genes (Basel). 2019. PMID: 31075974 Free PMC article. Review.
Cited by 11 articles
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.JHEP Rep. 2020 Mar 29;2(3):100112. doi: 10.1016/j.jhepr.2020.100112. eCollection 2020 Jun. JHEP Rep. 2020. PMID: 32462119 Free PMC article.
Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B.Virol J. 2020 Mar 18;17(1):40. doi: 10.1186/s12985-020-01314-0. Virol J. 2020. PMID: 32188476 Free PMC article.
Chronic Viral Hepatitis: Current Management and Future Directions.Hepatol Commun. 2020 Jan 20;4(3):329-341. doi: 10.1002/hep4.1480. eCollection 2020 Mar. Hepatol Commun. 2020. PMID: 32140652 Free PMC article. Review.
Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.Cells. 2020 Feb 20;9(2):493. doi: 10.3390/cells9020493. Cells. 2020. PMID: 32093411 Free PMC article. Review.
Peculiarities in the designations of hepatitis B virus genes, their products, and their antigenic specificities: a potential source of misunderstandings.Virus Genes. 2020 Apr;56(2):109-119. doi: 10.1007/s11262-020-01733-9. Epub 2020 Feb 6. Virus Genes. 2020. PMID: 32026198 Free PMC article.